Lee Ainslie's ROIV Position Overview
Lee Ainslie (via Maverick Capital LTD) currently holds 1.63 M shares of Roivant Sciences Ltd. (ROIV) worth $45.07 M, representing 0.52% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Lee Ainslie has initiated a new position in ROIV, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Lee Ainslie's Roivant Sciences (ROIV) Holding Value Over Time
Track share changes against reported price movement
Quarterly Roivant Sciences (ROIV) Trades by Lee Ainslie
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +1.63 M | New Buy | 1.63 M | $27.70 |
Lee Ainslie's Roivant Sciences Investment FAQs
Lee Ainslie first purchased Roivant Sciences Ltd. (ROIV) in Q1 2026, acquiring 1,626,940 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Lee Ainslie has held Roivant Sciences Ltd. (ROIV) for 1 quarters since Q1 2026.
Lee Ainslie's largest addition to Roivant Sciences Ltd. (ROIV) was in Q1 2026, adding 1,626,940 shares worth $45.07 M.
According to the latest 13F filing for Q1 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 1,626,940 shares of Roivant Sciences Ltd. (ROIV), valued at approximately $45.07 M.
As of the Q1 2026 filing, Roivant Sciences Ltd. (ROIV) represents approximately 0.52% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.
Lee Ainslie's peak holding in Roivant Sciences Ltd. (ROIV) was 1,626,940 shares, as reported at the end of Q1 2026.